Loading…
AbCellera Biologics Inc. is projected to rise to $6.93 by 2027, a +22% move from its current price of $5.69. ABCL is currently trading below its 50-day average (a bearish sign). Technical indicators currently lean sell.
A data-driven summary — not financial advice. See the full breakdown below.
Live market data via Yahoo Finance · updated 7/31/2026
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Aug 1 | $5.45 | $5.70 | $5.95 | +0.11% |
| Aug 2 | $5.36 | $5.70 | $6.07 | +0.22% |
| Aug 3 | $5.29 | $5.71 | $6.16 | +0.33% |
| Aug 4 | $5.23 | $5.72 | $6.24 | +0.44% |
| Aug 5 | $5.18 | $5.72 | $6.32 | +0.55% |
| Aug 6 | $5.14 | $5.73 | $6.38 | +0.66% |
| Aug 7 | $5.10 | $5.73 | $6.45 | +0.77% |
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Week 1 | $5.10 | $5.73 | $6.45 | +0.77% |
| Week 2 | $4.89 | $5.78 | $6.82 | +1.55% |
| Week 3 | $4.75 | $5.82 | $7.13 | +2.33% |
| Week 4 | $4.64 | $5.87 | $7.42 | +3.12% |
| Week 5 | $4.55 | $5.91 | $7.69 | +3.91% |
| Week 6 | $4.47 | $5.96 | $7.94 | +4.71% |
| Week 7 | $4.40 | $6.00 | $8.19 | +5.52% |
Short-term targets derived from the forecast trend and recent volatility. Highly uncertain — not financial advice.
AbCellera Biologics Inc. engages in discovering and developing antibody-based medicines for indications with unmet medical need in the United States. Its lead product ABCL635 is a non-hormonal medicine, which is in Phase 2 clinical trial to treat moderate-to-severe vasomotor symptoms; and ABCL575 is a fully human, half-life extended monoclonal antibody, which is in in a Phase 1 clinical trial for treating T-cell-mediated autoimmune conditions, such as atopic dermatitis.
The company has a research collaboration and license agreement with Eli Lilly and Company; AbbVie Inc.; Jazz Pharmaceuticals plc to develop T-cell engaging (TCE) multispecific antibodies; and partnership agreement with Viking Global Investors & ArrowMark Partners and Biogen Inc. AbCellera Biologics Inc. was incorporated in 2012 and is headquartered in Vancouver, Canada.
AbCellera Biologics Inc. (ABCL) is a healthcare company focused on antibody-based medicines. The stock is currently priced at $5.69, with a market cap of $1.74B and a rank of 2011.
The price outlook shows a path of upside potential over the forecast horizon. In 2026 the average price is $5.69 with a min of $2.78 and a max of $8.51 and a neutral sentiment. From 2027 onward, the forecast turns bullish, with rising averages and strong upside into the late 2040s and 2050s.
By 2050 the average is $125.06 and the max $284.73, with a bullish sentiment and a long-run upside that translates into substantial projected ROI.
A major floor 42.5% below — a decisive break under it would weaken the trend.
The nearest floor, 7.7% below — buyers have tended to step in here.
The nearest ceiling, 42.7% above — a clean break opens room to run.
A major ceiling 62.1% above — clearing it would confirm fresh momentum.
Key ABCL support and resistance from recent price action — levels where the trend has historically paused or reversed. Percentages are the distance from the current price.
A snapshot of ABCL market posture derived from its technical indicators and recent volatility. Higher trend and alignment lean bullish; higher risk means larger swings.
Technical Analysis
Indicators computed on daily closing prices.
| Period | SMA | Action | EMA | Action |
|---|---|---|---|---|
| MA 5 | $5.39 | Buy | $5.53 | Buy |
| MA 10 | $5.66 | Buy | $5.71 | Sell |
| MA 20 | $6.38 | Sell | $6.00 | Sell |
| MA 50 | $6.04 | Sell | $5.86 | Sell |
| MA 100 | $4.97 | Buy | $5.31 | Buy |
| MA 200 | $4.48 | Buy | $4.74 | Buy |
| Name | Value | Action |
|---|---|---|
| RSI (14) | 44.85 | Neutral |
| Stoch RSI (14) | 48.92 | Neutral |
| CCI (20) | -61.00 | Neutral |
| Williams %R (14) | -70.47 | Info |
| MACD (12,26,9) | -0.15 | Sell |
| ROC (12) | -15.58 | Sell |
| Bollinger %B (20,2) | 0.30 | Neutral |
| Stochastic %K (14) | 29.53 | Neutral |
| TRIX (15) | -0.18 | Sell |
| Awesome (5,34) | -0.92 | Sell |
| Ultimate (7,14,28) | 38.54 | Neutral |
| Momentum (10) | -0.47 | Sell |
| Aroon Osc (25) | -76.00 | Sell |
| Hull MA (9) | 5.30 | Buy |
| ADX (14) | 18.21 | Neutral |
| ATR (14) | 0.26 | Info |
The 30-day technical picture shows bullish sentiment. RSI14 is 40, with the 50-day simple moving average at $6.04 and the 200-day simple moving average at $4.48. Short-term support sits at $5.25 and resistance at $8.12, framing a 30-day range of $4.25 to $7.62.
| Year | Min | Avg | Max | ROI | Sentiment |
|---|---|---|---|---|---|
| $2.78 | $5.69 | $8.51 | 0% | Neutral | |
| $5.21 | $6.93 | $9.90 | +22% | Bullish | |
| $6.00 | $8.37 | $12.66 | +47% | Bullish | |
| $6.94 | $10.10 | $15.93 | +77% | Bullish | |
| $7.51 | $11.34 | $18.55 | +99% | Bullish | |
| $10.91 | $17.05 | $28.74 | +200% | Bullish | |
| $13.09 | $21.12 | $36.60 | +271% | Bullish | |
| $13.09 | $21.79 | $38.69 | +283% | Bullish | |
| $13.57 | $23.26 | $42.24 | +309% | Bullish | |
| $13.68 | $24.14 | $44.75 | +324% | Bullish | |
| $24.04 | $48.60 | $98.09 | +754% | Bullish | |
| $56.28 | $125.06 | $284.73 | +21.0x | Bullish |
Current year — the forecast is anchored to the live price, so ROI shows 0%.
| Month | Min | Avg | Max | Change |
|---|---|---|---|---|
| July 2026 | $2.78 | $5.69 | $6.67 | +0.00% |
| August 2026 | $5.14 | $6.11 | $7.49 | +7.36% |
| September 2026 | $5.22 | $6.29 | $7.88 | +2.94% |
| October 2026 | $5.03 | $6.13 | $7.81 | -2.50% |
| November 2026 | $5.06 | $6.22 | $8.03 | +1.47% |
| December 2026 | $5.25 | $6.51 | $8.51 | +4.70% |
Click any year to see its month-by-month ABCL forecast. Min / Avg / Max are a bear / base / bull scenario; ROI is the projected move from the current price. Change is the month-over-month move in the average. Estimates, not guarantees.
The ABCL price prediction for 2026 points to an average of $5.69 (low $2.78, high $8.51) — a potential gain of 0% on today's $5.69. A consolidation phase looks the most probable path here.
In 2027, ABCL is projected to trade between $5.21 and $9.90, averaging $6.93 — a potential gain of +22% from today's $5.69. That is up +22% on the projected 2026 average. Momentum favours further upside here.
AbCellera Biologics Inc.'s 2028 outlook centres on $8.37, within a $6.00 to $12.66 range. That is up +21% on the projected 2027 average. That marks a +47% change versus current levels. Buyers look set to stay in control over this stretch.
By 2029, ABCL could reach as high as $15.93, with a base case around $10.10 and support toward $6.94 — roughly +77% from $5.69. Momentum favours further upside here.
Expect ABCL to range from $7.51 to $18.55 through 2030. The $11.34 average target implies a +99% move from current prices. That is up +12% on the projected 2029 average. Buyers look set to stay in control over this stretch.
The ABCL price prediction for 2031 points to an average of $17.05 (low $10.91, high $28.74) — a potential gain of +200% on today's $5.69. Momentum favours further upside here.
In 2032, ABCL is projected to trade between $13.09 and $36.60, averaging $21.12 — a potential gain of +271% from today's $5.69. That is up +24% on the projected 2031 average. Buyers look set to stay in control over this stretch.
AbCellera Biologics Inc.'s 2033 outlook centres on $21.79, within a $13.09 to $38.69 range. That is up +3% on the projected 2032 average. That marks a +283% change versus current levels. Momentum favours further upside here.
By 2034, ABCL could reach as high as $42.24, with a base case around $23.26 and support toward $13.57 — roughly +309% from $5.69. Buyers look set to stay in control over this stretch.
Expect ABCL to range from $13.68 to $44.75 through 2035. The $24.14 average target implies a +324% move from current prices. That is up +4% on the projected 2034 average. Momentum favours further upside here.
The ABCL price prediction for 2040 points to an average of $48.60 (low $24.04, high $98.09) — a potential gain of +754% on today's $5.69. Buyers look set to stay in control over this stretch.
In 2050, ABCL is projected to trade between $56.28 and $284.73, averaging $125.06 — a potential gain of +21.0x from today's $5.69. That is up +157% on the projected 2040 average. Momentum favours further upside here.
Investing $1,000 in ABCL today (≈ 175.746924 ABCL) could be worth
$21,979.25
+$20,979.25 (+2098%) by 2050 · US Dollar
Based on the average projected ABCL price of $125.06 in 2050.
Based on the base (average) forecast scenario. FX rates are indicative. Estimates only — not financial advice.
See what a past investment in ABCLwould be worth at today's price.
$1,000 invested in ABCL on Jul 30, 2025 (≈ 218.818373 ABCL) would be worth
$1,245.08
+$245.08 (+24.5%) today · 1.25× · US Dollar
Based on a ABCL entry price of $4.57 vs. today's $5.69.
| Invested | Entry price | Value today | Return |
|---|---|---|---|
| 1 week ago | $5.67 | $1,003.53 | +0.4% |
| 1 month ago | $7.85 | $724.84 | -27.5% |
| 3 months ago | $4.43 | $1,284.42 | +28.4% |
| 6 months ago | $3.62 | $1,571.82 | +57.2% |
| 1 year ago | $4.57 | $1,245.08 | +24.5% |
| All time (5.0y) ago | $15.82 | $359.67 | -64.0% |
Past performance from historical market data — it does not predict future results. FX rates are indicative. Not financial advice.
Enter a price to see how it sits against our ABCL forecast.
Our base-case forecast reaches $11.00 around 2030.
Implied market cap at $11.00: $3.36B
The multi-year forecast points to a rising price path with progressively higher averages and notable ROI gains. For 2030 the min/max/avg are $7.51 / $18.55 / $11.34 with an ROI of 99.4% and bullish sentiment. The forecast continues to reflect bullish momentum through 2040, where the average is $48.60 with a max of $98.09 and an ROI of 754.2%.
By 2050 the average reaches $125.06 with a max of $284.73 and an ROI of 2097.9%.
These are estimates, not guarantees. The outlook shows a sustained bullish tilt in the later years, but actual results depend on market conditions and clinical outcomes. The years 2031 and beyond also show strong gains in average price and ROI, underscoring a long-run upward trajectory in the forecast, while acknowledging inherent uncertainty in future performance.
Tap a question to reveal the answer.
The 2030 forecast shows an average price of $11.34, with a min of $7.51 and a max of $18.55, and a projected ROI of 99.4%, with bullish sentiment.
The long-term forecast is bullish for many years, with rising averages and ROIs (for example, 2031 avg $17.05 ROI 199.6%; 2050 avg $125.06 ROI 2097.9%), though these are estimates and not guarantees.
Yes. The 2040 max is $98.09 and the 2030 max is $18.55, while the 2050 max is $284.73, so reaching $50 is supported by the forecast in the 2040–2050 period.
Current price is $5.69 and market cap is $1.74B.
RSI14 is 40. The 50-day SMA is $6.04 and the 200-day SMA is $4.48. Short-term support is at $5.25 and resistance at $8.12, with a 30-day price range of $4.25 to $7.62.
AbCellera Biologics Inc. Community Discussion
0Share your AbCellera Biologics Inc. price prediction and read what the community thinks. Be respectful — comments are public and not financial advice.
Be the first to share your prediction…
What's your take? Add a comment above to start the conversation.